Aerie Pharmaceuticals acquired by Alcon

The deal will expand Alcon's footprint in the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&D capabilities to existing commercial efforts.

Alcon and Aerie Pharmaceuticals have announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie.

According to a news release from Alcon, the deal will expand its footprint in the ophthalmic pharmaceutical space and is expected to add broader pharmaceutical R&D capabilities to Alcon’s existing commercial efforts, maximizing the value of its portfolio. The deal is valued at about $753 million.

Through the transaction, Alcon will add the commercial products netarsudil and latanoprost ophthalmic solution (Rocklatan) 0.02%/0.005% and netarsudil ophthalmic solution (Rhopressa) 0.02%, as well as AR-15512, a Phase 3 product candidate for dry eye disease, and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates.

The transaction complements Alcon’s recent expansion into the ophthalmic pharmaceutical eye drop space, including acquisitions of the exclusive U.S. commercialization rights to Simbrinza from Novartis in April 2021 and of Eysuvis and Inveltys from Kala Pharmaceuticals in May of this year.

“Alcon is passionate about innovative treatments in eye care, especially in core disorders such as glaucoma and dry eye, which have significant patient impact,” said David Endicott, CEO of Alcon. “We have a 75-year history focused specifically on the eye and bring established expertise in development and commercial execution."

Endigott added that Aerie is a natural fit with on-market and pipeline products, and R&D capabilities that offer the infrastructure needed to expand Alcon's ophthalmic pharmaceutical presence.

"As we continue to broaden our portfolio across glaucoma, retina and ocular surface disease, we are excited to help even more patients see brilliantly," he said in the statement.

Raj Kannan, CEO of Aerie Pharmaceuticals, said in the news release that the company is looking forward to joining the Alcon family.

“I am so proud of the Aerie team and the innovation we’ve pioneered,” Kannan said in the news release. “Alcon is the right strategic and financial partner to maximize the potential of Aerie’s commercial franchise and our growing portfolio of pipeline assets. Alcon’s global infrastructure, financial resources, and commercial capabilities will accelerate the standard of care by helping more patients have access to Aerie’s innovative products. I am confident that this combination with Alcon is in the best interest of patients and our shareholders.”

According to the news release, the purchase price of $15.25 per share represents a premium of 37% to Aerie’s last closing price and represents an equity value of approximately $770 million. The transaction was approved by the board of directors of each company.

Aerie’s most recent financial guidance for total glaucoma franchise net product revenue is $130 million to 140 million for full year 2022. The transaction is expected to be accretive to Alcon’s core diluted Earnings Per Share (EPS) in 2024. The transaction is anticipated to close in the fourth quarter of 2022, subject to the approval of Aerie’s stockholders and the satisfaction of customary closing conditions, including clearance under the Hart-Scott Rodino Antitrust Improvements Act. Alcon intends to fund the acquisition through short-term and long-term debt.

J.P. Morgan acted as Alcon’s financial advisor for the transaction, and Alcon’s legal advisor was Skadden, Arps, Slate, Meagher & Flom LLP. Goldman Sachs & Co. LLC acted as Aerie’s financial advisor for the transaction, and Aerie’s legal advisor was Fried, Frank, Harris, Shriver & Jacobson LLP.

Reference

1. Ophthalmology Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030.